BofA lifts gold target to $5,000/oz, sees silver staying in deficit
Chief Scientific Officer of Akero Therapeutics (NASDAQ:AKRO), Timothy Rolph, sold a total of $576,001 worth of company stock on October 7, 2025. The sales involved 12,500 shares of common stock. The transaction comes as the $4.3 billion biotech company trades near its 52-week high of $58.40, having gained over 16% in the past week. InvestingPro analysis suggests the stock is currently trading above its Fair Value.
According to a Form 4 filing with the Securities and Exchange Commission, Rolph sold 11,463 shares at a weighted average price ranging from $45.545 to $46.54, resulting in a total value of $527,448. Additionally, Rolph sold 1,037 shares at a weighted average price ranging from $46.57 to $47.10, resulting in a total value of $48,553. Analysts maintain a bullish outlook on the stock, with price targets ranging from $54 to $109.
On the same day, Rolph also exercised options to acquire 12,500 shares of Akero Therapeutics common stock at a price of $28.35, for a total value of $354,375.
Following these transactions, Rolph directly owns 166,571 shares of Akero Therapeutics.
In other recent news, Novo Nordisk has announced a definitive agreement to acquire Akero Therapeutics for up to $5.2 billion in cash. As part of the deal, Akero shareholders will receive $54.00 per share, totaling approximately $4.7 billion in equity value. They will also receive a Contingent Value Right worth $6.00 per share, contingent upon the U.S. regulatory approval of efruxifermin (EFX) by June 30, 2031. Akero Therapeutics is set to present data from two Phase 2b studies of EFX at the upcoming American Association for the Study of Liver Diseases annual meeting. Meanwhile, H.C. Wainwright has initiated coverage on Akero with a Buy rating and a price target of $72.00, citing the potential of EFX in reversing cirrhosis. Morgan Stanley has reiterated an Overweight rating on Akero with an $84.00 price target, following Novo Nordisk’s decision to discontinue its own MASH treatment. Additionally, TD Cowen has also initiated coverage on Akero with a Buy rating and a $76.00 price target, noting the strong efficacy data of EFX. These developments highlight Akero’s growing significance in the treatment of metabolic dysfunction-associated steatohepatitis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.